Αρχική World News Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with... World News Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions Από Ogkologos - 23 Ιουνίου, 2026 292 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the WU-KONG28 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Can Cancer Symptoms Be Mistaken for Menopause? 26 Αυγούστου, 2021 FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma 28 Φεβρουαρίου, 2024 ESMO Launches Clinical Trials Funding Initiative to Optimise Cancer Care Pathways 10 Σεπτεμβρίου, 2026 EMA recommends granting a marketing authorisation for daraxonrasib 12 Νοεμβρίου, 2026 Φόρτωση περισσοτέρων HOT NEWS Metastatic Breast Cancer: ESMO Living Guideline Biomarker Analyses in Patients with HER2-positive or HER2-low Gastric and Gastro-oesophageal... ¿Qué deben saber las personas con cáncer sobre el consumo de... Identification of Potential Biomarkers for Clinical Benefit Following Dual Neoadjuvant Anti-HER2...